Polaryx Therapeutics (PLYX) Return on Assets (2026)
Polaryx Therapeutics (PLYX) posted quarterly Return on Assets of 0.02% for Q1 2026.
Polaryx Therapeutics (PLYX) Return on Assets (2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Return on Assets for 1 consecutive years, with 0.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Assets changed N/A year-over-year to 0.02%; the TTM figure through Mar 2026 stood at 0.02% (changed N/A YoY), while the FY2025 annual figure was 0.03%, changed N/A from the prior year.
- Return on Assets held at 0.02% in Q1 2026 per PLYX's latest filing.
- Across five years, Return on Assets topped out at 0.02% in Q1 2026 and bottomed at 0.02% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 0.00% |
| 10 | Polaryx Therapeutics | 101.14 Mn | 89.60 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01% |
| Mar 31, 2026 | -0.02% |